English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Trending Topics
    Sensex Live Ceigall India Shares Pace Digitek IPO GMP Anand Rathi Share and Stock Brokers IPO

    business

    Dishman Pharma eyes 15% topline, bottomline growth in FY12

    In an interview with CNBC-TV18, VVS Murthy, CFO, Dishman Pharma said the company is expecting 15% top-line and bottom-line growth in FY12.

    first published: Jun 13, 2011 03:30 pm

    LATEST VIDEOS

    Watch More →

    A collection of the most-viewed Moneycontrol videos.

    Watch and Follow our leading shows

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347